GROEBKE ZBINDEN KATRIN,NORCROSS ROGER,PFLIEGER PHILIPPE
申请号：
NZ59957710
公开号：
NZ599577A
申请日:
2010.12.17
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
The disclosure relates to substituted benzamide derivatives of formula I wherein R R1 n o p R2 Y R&rsquo&rsquo and q are as defined in the specification or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders. compounds of the disclosure include: (RS)-4-chloro-N-(5-piperidin-3-yl)pyridin-2-yl)benzamide hydrochloride, (RS)-3-(2-Chloro-phenyl)-N-(4-pyrrolidin-3-yl-phenyl)-propionamide, (RS)-2-(4-Chloro-phenyl)-N-(4-pyrrolidin-3-yl-phenyl)-acetamide, (S)-4-chlorobenzyl-4-(piperidin-3-yl)phenylcarbamate, (S)-N-(4-(1,4-Oxazepan-2-yl)phenyl)-3-chlorobenzamide, (RS)-2-Ethoxy-N-(4-(morpholin-2-yl)phenyl)isonicotinamide, (RS)-N-(4-(Morpholin-2-yl)phenyl)-2-(pyrazin-2-yl)thiazole-4-carboxamide, and (RS)-5-Chloro-pyrazine-2-carboxylic acid (4-piperidin-3-yl-phenyl)-amide
